MA52789A - Méthodes de traitement du cancer avec des anticorps anti-pd-1 - Google Patents

Méthodes de traitement du cancer avec des anticorps anti-pd-1

Info

Publication number
MA52789A
MA52789A MA052789A MA52789A MA52789A MA 52789 A MA52789 A MA 52789A MA 052789 A MA052789 A MA 052789A MA 52789 A MA52789 A MA 52789A MA 52789 A MA52789 A MA 52789A
Authority
MA
Morocco
Prior art keywords
antibodies
cancer treatment
treatment methods
cancer
methods
Prior art date
Application number
MA052789A
Other languages
English (en)
Inventor
Lokesh Jain
Mallika Lala
Mengyao Li
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA52789A publication Critical patent/MA52789A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA052789A 2018-02-13 2019-02-08 Méthodes de traitement du cancer avec des anticorps anti-pd-1 MA52789A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862630038P 2018-02-13 2018-02-13
US201862732828P 2018-09-18 2018-09-18

Publications (1)

Publication Number Publication Date
MA52789A true MA52789A (fr) 2021-04-14

Family

ID=67620026

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052789A MA52789A (fr) 2018-02-13 2019-02-08 Méthodes de traitement du cancer avec des anticorps anti-pd-1

Country Status (15)

Country Link
US (2) US20210047408A1 (fr)
EP (1) EP3752180A4 (fr)
JP (2) JP2021513541A (fr)
KR (1) KR20200119844A (fr)
CN (1) CN111712255A (fr)
AU (1) AU2019220495A1 (fr)
BR (1) BR112020016331A8 (fr)
CA (1) CA3090995A1 (fr)
CL (1) CL2020002075A1 (fr)
IL (1) IL276303A (fr)
MA (1) MA52789A (fr)
MX (1) MX2020008445A (fr)
RU (1) RU2020129827A (fr)
SG (1) SG11202007590TA (fr)
WO (1) WO2019160751A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
WO2021061719A1 (fr) 2019-09-27 2021-04-01 Merck Sharp & Dohme Corp. Méthodes de traitement du cancer du sein métastatique triple négatif avec des anticorps anti-pd-1
EP4076385A1 (fr) 2019-12-20 2022-10-26 Formycon AG Formulations d'anticorps anti-pd1
EP4076521A4 (fr) * 2019-12-20 2024-01-24 Merck Sharp & Dohme LLC Procédés de traitement d'un cancer à l'aide d'une combinaison d'un antagoniste de pd-1, d'un antagoniste d'ilt4, et d'agents chimiothérapeutiques
CN112326961B (zh) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备
CN112394102B (zh) * 2020-11-05 2023-05-26 上海交通大学医学院附属瑞金医院 一种检测垂体功能减退症的标志物及其应用
KR20240024941A (ko) 2021-06-23 2024-02-26 포르미콘 아게 항-pd1 항체의 제제
EP4373857A1 (fr) * 2021-07-20 2024-05-29 Merck Sharp & Dohme LLC Méthodes de traitement d'un cancer à l'aide d'une combinaison d'un antagoniste de pd-1, d'un antagoniste d'ilt4 et d'agents chimiothérapeutiques
CN113893343A (zh) * 2021-10-16 2022-01-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗宫颈癌患者的药物中的用途
WO2023114346A2 (fr) * 2021-12-16 2023-06-22 Merck Sharp & Dohme Llc Biomarqueurs permettant de prédire l'éligibilité pour polythérapie anti-ilt4 et anti-pd-1
CN115925954A (zh) * 2022-12-28 2023-04-07 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2170959T3 (pl) * 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
JP6014116B2 (ja) 2011-03-31 2016-10-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療
CA2955612C (fr) * 2014-07-18 2022-05-17 Advaxis, Inc. Combinaison d'un antagoniste de pd-1 et d'un vaccin a base de listeria pour le traitement du cancer
US10695426B2 (en) * 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
CN106999582A (zh) 2014-11-13 2017-08-01 约翰·霍普金斯大学 检查点阻断和微卫星不稳定性
AR103726A1 (es) * 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
KR20170140316A (ko) * 2015-04-28 2017-12-20 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용한 pd-l1-양성 흑색종의 치료
WO2017165125A1 (fr) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Utilisation d'un antagoniste de pd-1 et d'un anticorps anti-ccr2 dans le traitement du cancer
EP3464369A1 (fr) * 2016-06-03 2019-04-10 Bristol-Myers Squibb Company Anticorps anti-pd-1 utilisé dans un procédé de traitement d'une tumeur
EP3630840A1 (fr) * 2017-06-01 2020-04-08 Bristol-Myers Squibb Company Méthodes de traitement d'une tumeur au moyen d'un anticorps anti-pd-1

Also Published As

Publication number Publication date
US20210047408A1 (en) 2021-02-18
RU2020129827A (ru) 2022-03-14
US20240026003A1 (en) 2024-01-25
AU2019220495A1 (en) 2020-08-13
SG11202007590TA (en) 2020-09-29
BR112020016331A8 (pt) 2023-02-07
IL276303A (en) 2020-09-30
JP2021513541A (ja) 2021-05-27
WO2019160751A3 (fr) 2020-09-10
EP3752180A2 (fr) 2020-12-23
EP3752180A4 (fr) 2021-12-15
CN111712255A (zh) 2020-09-25
CA3090995A1 (fr) 2019-08-22
BR112020016331A2 (pt) 2020-12-15
KR20200119844A (ko) 2020-10-20
WO2019160751A2 (fr) 2019-08-22
CL2020002075A1 (es) 2020-10-23
MX2020008445A (es) 2020-09-28
JP2024038251A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA52962A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA49144A (fr) Polythérapies pour le traitement du cancer
MA51844A (fr) Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
MA51815A (fr) Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA47719A (fr) Esketamine pour le traitement de la dépression
MA48637A (fr) Polythérapies pour le traitement du cancer
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
MA50409A (fr) Polythérapies pour le traitement du cancer
MA53506A (fr) Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules